A comparison of three fibrinolytic agents in prevention of intra-abdominal adhesions.
Topal
E
E
Uludag University Faculty of Medicine, Department of General Surgery, Bursa, Turkey.
Ozturk
E
E
Sen
G
G
Yerci
O
O
Yilmazlar
T
T
D000818:Animals; D004195:Disease Models, Animal; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005170:Factor X; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D000077425:Fondaparinux; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D010532:Peritoneal Diseases / Q000175:diagnosis / Q000517:prevention & control*; D011134:Polysaccharides / Q000008:administration & dosage; D011486:Protein C / Q000008:administration & dosage; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000008:administration & dosage; D000267:Tissue Adhesions / Q000517:prevention & control; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D011134:Polysaccharides; D011486:Protein C; D011994:Recombinant Proteins; D005170:Factor X; D010959:Tissue Plasminogen Activator; D000077425:Fondaparinux; C421124:drotrecogin alfa activated